Access Pharmaceuticals, Inc.
Drug-delivery firm restructures to focus on oncology therapeutics; oral care business sold
Published in Pharma Investments, Ventures and Law Weekly, November 13th, 2005
Access sold its interest in Aphthasol, all OraDisc products, and all Residerm products. In addition, Uluru has licensed Access' nanoparticle hydrogel aggregate technology. Access received $8.7 million at the closing of the agreement and may receive up to $3.7 million within 12 months after closing, and will receive an additional $1 million within 24 months after closing. Additional payments of up to $7 million will be made upon the achievement of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- ATS Medical, Inc.
Cardiac surgery device maker closes $19M convertible senior note offering - Able Laboratories, Inc.
Generic drug maker files application with bankruptcy court for authority to sell assets - Acuity Medical
Macular degeneration device improves vision in 26% of treated eyes in trial - Aerie Pharmaceuticals, Inc.
Glaucoma therapy developer closes $21M series A financing - Aler Institute, North Garden
When adjusted for inflation, biomedical research funding has doubled from 1994 to 2003 - Alinea Pharmaceuticals, Inc.
Diabetes drug maker announces $45M series A financing - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
